Kane Biotech Receives United States Patent for Methods of Reducing Biofilm Formation

WINNIPEG, MANITOBA -- (MARKET WIRE) -- 01/23/07 -- Kane Biotech Inc. (TSX VENTURE: KNE), a biotechnology company engaged in the development of products that prevent and disperse bacterial biofilms, is pleased to announce that it has received Patent No. 7,144,992 entitled "Synergistic Antimicrobial Compositions and Methods for Reducing Biofilm Formation", by the US Patent and Trademark Office. This patent protects the methods of reducing biofilm formation in a variety of applications including medical devices, among others.

"The receipt of this patent provides further strength to our patent estate and enhances our growing pipeline of technologies that prevent and disperse bacterial biofilms", stated Mr. Gord Froehlich, President of Kane Biotech Inc.

Biofilms are increasingly recognized as the root cause of a number of serious problems, as they corrode drinking water mains, contaminate equipment in the food and beverage industry, infect medical devices and cause chronic infections in humans and animals. Biofilms pose a human health problem, as they develop on surfaces such as catheters and prosthetic implants, inner ears, teeth, gums, lungs and the urogenital tract. An estimated 80% of all human bacterial infections involve biofilms.

About Kane Biotech Inc.

Kane Biotech is a biotechnology company engaged in the development of products to prevent and disperse bacterial biofilms. Biofilms develop when bacteria, and other microorganisms, form a protective matrix that acts as a shield against attack. When in a biofilm, bacteria become highly resistant to antibiotics, biocides, disinfectants, high temperatures and host immune responses. This resiliency contributes to human health problems such as recurrent urinary tract infections, medical device associated infections and tooth decay.

Kane Biotech Inc. uses a patent protected technology based on molecular mechanisms of biofilm formation and methods for finding compounds that inhibit or disrupt biofilms. The Company has evidence that this technology has potential to significantly improve the ability to prevent and/or destroy biofilms in several medical and industrial applications.

Certain information contained in this press release may be forward-looking and is subject to risks and uncertainties. Although the Company believes that the expectations contained herein are reasonable, it can give no assurances such forward-looking statements will prove correct. Information is provided from sources deemed to be reliable.

The TSX Venture Exchange has neither approved nor disapproved the contents of this press release.

Contacts:
Kane Biotech Inc.
Sandra Benson
Manager, Investor Relations
(204) 478-5602
(204) 453-1314 (FAX)
Email: sbenson@kanebiotech.com

Kane Biotech Inc.
Gord Froehlich
President
(204) 453-1301
Email: info@kanebiotech.com
Website: www.kanebiotech.com

Released January 23, 2007